Investors

2015 Press Releases

Keyword Search
2017 | 2016 | 2015 | 2014
DateTitle Download Print
12/10/15BrainStorm Reschedules Corporate Update Conference Call to January 11, 2016Download PDFPrinter Friendly Version
12/07/15BrainStorm Cell Therapeutics Announces Appointment of Dr. Revital Geffen-Aricha as Vice President of Research & DevelopmentDownload PDFPrinter Friendly Version
12/02/15BrainStorm Hosting Conference Call to Update Shareholders on Important DevelopmentsDownload PDFPrinter Friendly Version
12/01/15BrainStorm and Octane Biotech Announce Success in Cocoon™ Application Development Based on Customized Bioreactor for NurOwn® Stem CellsDownload PDFPrinter Friendly Version
11/30/15BrainStorm Awarded Additional $735,000 Non-Dilutive Grant for 2015 from Israel's Office of the Chief ScientistDownload PDFPrinter Friendly Version
11/17/15BrainStorm Cell Therapeutics Reports Third Quarter 2015 Financial Results And Provides Corporate UpdateDownload PDFPrinter Friendly Version
11/09/15BrainStorm Cell Therapeutics Announces Positive DSMB Review in Phase 2 Trial of NurOwn® in ALSDownload PDFPrinter Friendly Version
10/16/15BrainStorm Strengthens Intellectual Property Position - Granted Patent for Company's NurOwn® Technology PlatformDownload PDFPrinter Friendly Version
10/08/15BrainStorm Cell Therapeutics' Chief Scientific Advisor to Present At The 2015 FENS-RM in Thessaloniki, GreeceDownload PDFPrinter Friendly Version
10/07/15BrainStorm Announces Treatment of Final Patient in US Multicenter Double Blinded Phase 2 ALS TrialDownload PDFPrinter Friendly Version
10/01/15BrainStorm Cell Therapeutics to Present at 2015 Stem Cell Meeting on the MesaDownload PDFPrinter Friendly Version
09/22/15BrainStorm Announces Appointment of Chaim Lebovits as Chief Executive OfficerDownload PDFPrinter Friendly Version
09/02/15BrainStorm Cell Therapeutics to Present at Rodman & Renshaw 17th Annual Global Investment ConferenceDownload PDFPrinter Friendly Version
08/13/15BrainStorm Cell Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate UpdateDownload PDFPrinter Friendly Version
08/11/15BrainStorm Cell Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of NurOwn® in ALSDownload PDFPrinter Friendly Version
08/06/15BrainStorm Cell Therapeutics to Report Second Quarter 2015 Financial Results on Thursday, August 13 Printer Friendly Version
08/03/15BrainStorm Strengthens Executive Team: Announces the Appointment of Yoram Bibring as Chief Financial OfficerDownload PDFPrinter Friendly Version
07/06/15BrainStorm Cell Therapeutics to Present at Cantor Fitzgerald’s Inaugural Healthcare ConferenceDownload PDFPrinter Friendly Version
06/29/15BrainStorm Cell Therapeutics Added to Russell Microcap® IndexDownload PDFPrinter Friendly Version
06/16/15BrainStorm Cell Therapeutics at the BIO International ConventionDownload PDFPrinter Friendly Version
05/14/15BrainStorm Cell Therapeutics Announces First Quarter 2015 Financial Results and Provides Corporate UpdateDownload PDFPrinter Friendly Version
05/11/15BrainStorm Cell Therapeutics to Present at Upcoming ConferencesDownload PDFPrinter Friendly Version
05/07/15BrainStorm Cell Therapeutics to Report First Quarter 2015 Financial Results on Thursday, May 14Download PDFPrinter Friendly Version
04/21/15BrainStorm's NurOwn® Demonstrates a Statistically Significant Effect in ALS PatientsDownload PDFPrinter Friendly Version
04/14/15BrainStorm Cell Therapeutics to Present Positive NurOwn® Phase 2a Clinical Data at American Academy of Neurology Annual MeetingDownload PDFPrinter Friendly Version
03/26/15BrainStorm Announces Financial Results for 2014Download PDFPrinter Friendly Version
03/19/15BrainStorm Cell Therapeutics to Report Fourth Quarter and Full Year 2014 Financial Results on Thursday, March 26Download PDFPrinter Friendly Version
03/18/15BrainStorm Cell Therapeutics to Present at 3rd Annual Regen Med Investor Day on March 25 in New YorkDownload PDFPrinter Friendly Version
02/09/15BrainStorm Receives Notice of Allowance for its NurOwn™ Technology Platform from Israel’s Patent OfficeDownload PDFPrinter Friendly Version
02/04/15BrainStorm CEO to Present at the 17th Annual BIO CEO & Investor ConferenceDownload PDFPrinter Friendly Version
02/03/15BrainStorm Announces Positive DSMB Recommendation in Ongoing Phase 2 Trial with NurOwn™ in ALSDownload PDFPrinter Friendly Version
01/26/15BrainStorm Announces Exceptional Preclinical Results of NurOwn™ in Mouse Autism ModelDownload PDFPrinter Friendly Version
01/08/15BrainStorm Enters Into Warrant Exercise Agreement for Approximately $13 Million in ProceedsDownload PDFPrinter Friendly Version
01/07/15BrainStorm Announces Receipt of Approximately $3.1 Million from Warrant ExercisesDownload PDFPrinter Friendly Version
01/06/15BrainStorm CEO to Present at Two Upcoming Investor ConferencesDownload PDFPrinter Friendly Version
01/05/15BrainStorm Announces Final Analysis of Phase 2a ALS Study Showing Nearly All Subjects Experienced Clinical Benefit from NurOwn™Download PDFPrinter Friendly Version